Skip to main contentSkip to navigationSkip to search
HNSA (, %) SEK
Hansa Biopharma logotype

Our Commitment

"At Hansa Biopharma we envision a world where patients with rare immunologic diseases can lead long and healthy lives.

We are dedicated to attaining market approval for the first treatment that potentially may enable kidney transplantation in highly sensitized patients."

Søren Tulstrup

President and CEO of Hansa Biopharma

Our Vision

A world where all patients with rare immunologic diseases can lead long and healthy lives.

Our Mission

We leverage our unique enzyme technology platform to develop innovative, lifesaving and life altering immunomodulating therapies, bring these to the patients with rare diseases who need them, and generate value to society at large.

"Our goal is to create value for patients, healthcare providers, societies and our shareholders. We are striving to develop therapies for patients with an unmet medical need and bringing our drugs all the way from the laboratory to the patients."

Recent Achievements

The European Commission has conditionally approved Idefirix (imlifidase) for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor.

We are in dialogue with the Food and Drug Administration regarding a regulatory path for the U.S. market.

Hansa’s research and development program is also advancing the Company’s enzyme technology to develop the next generation of IgG-cleaving enzymes with potentially lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology.

We have initiated three Phase 2 clinical studies in autoimmune indications; Guillain-Barré Syndrome (GBS), Goodpasture’s syndrome (anti-GBM antibody disease) and acute Antibody-Mediated Rejection (AMR) in kidney transplantation. The completion of enrollment of patients in the investigator initiated anti-GBM antibody disease study marks an important milestone for Hansa Biopharma’s expansion outside transplantation.

We have selected a lead candidate in the NiceR program and are exploring the opportunities for repeat dosing in a range of conditions including relapsing autoimmune diseases, chronic transplant rejection, pre-treatment in oncology and in combination with gene therapy.

Strategic Priorities

Advance Hansa's platform in new indications and therapeutic areas.

Commercialize Idefirix (imlifidase) in first markets and indications.

Build organizational capabilities and expand the technology platform.